Growth & Scale
Series A → Series C+
The pressure changes at A, B, C, and beyond. Growth has to be provable, not promised.
Validating the strategy against real numbers, scaling what's actually working, expanding into new markets globally, and getting ahead of the next round before investors start asking hard questions.
What "scale" actually means
Scale isn't just more of the same, pushed harder. It's a specific set of decisions:
CHANNELS
Direct and indirect working together — not chasing every channel, and not leaving an obvious one unused.
Portfolio
Broad enough to capture more of the opportunity, without diluting focus or spreading the team thin.
Price Leverage
Turning the value proposition into pricing power — not discounting your way to more volume.
Adjacencies
Identifying the next real opportunity close enough to the core to be credible, before chasing it.
Partners & Alliances
Strategic alliances that extend capability and credibility beyond what you can build alone — not the same as a sales channel.
De-risking looks different at this stage
Pre-seed and Series A were about proving the concept could work at all. From here, the question changes: does it hold up as you grow, across markets, without breaking? That's what B and C-stage investors are actually testing for.
The Real Bottleneck
Most companies at this stage have growth. What they don't have is proof it's repeatable — that it works beyond the first market and the first wave of customers.
Repeatability often requires capabilities and expertise different from what's in place.
What "provable" actually looks like
Pre-seed and Series A were about proving the concept could work at all. From here, the question changes: does it hold up as you grow, across markets, without breaking? That's what B and C-stage investors are actually testing for.
Unit Economics
Numbers that hold at volume, not just in the early, hand-managed cohorts.
Retention
Customers who stay and repeat, not just sign and churn.
Repeatability
The model working across cohorts and markets, not dependent on one team or one region getting it right.
Concentration Risk
Growth not sitting on one or two accounts that could walk away.
Scaling what's working, not just doing more of it
More spend and more headcount isn't a growth strategy — it's an amplifier. We validate which parts of the model are actually driving results before you scale them, so growth compounds instead of just costing more.
Expanding into new markets — deliberately, globally
The next market shouldn't be the obvious one by default, any more than the first one should have been. We help identify where the model actually transfers — across geographies, not just adjacent U.S. segments — before you commit resources to finding out the hard way.
Global doesn't mean everywhere at once. It means one market at a time, each one backed by evidence and the right partner, not a rollout that spreads the company thin before any of it is proven.
Real access to the partners scale requires
Channels, portfolio, and adjacency decisions aren't just analysis — they run on actual relationships. The same corporate network behind Vaxa's investor access also opens doors on the growth side.
Channel Partners
Corporate and distribution relationships for indirect channels, not a cold-outreach list.
Corporate Buyers
Access to the enterprise and corporate customers that prove the model at scale.
Market Entry Partners
Local partners in new markets, so expansion doesn't start from zero.
Concentration Risk
Relationships across North America, Europe, and beyond — not limited to where the company already operates.
What we actually do
01
Stress-test the strategy
Validate it holds up under real growth, not just early traction.
02
Scale what's proven
Double down on what's actually driving results, cut what's just adding cost.
03
Choose the next market deliberately
Evaluate expansion options globally, based on where the model transfers, not on proximity.
04
Set up the next raise
Position the business for its next round before the pressure hits — see Fundraising & Investor Readiness.